Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci.

Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci.

Btk is a cytoplasmic protein tyrosine kinase (PTK) that has been directly implicated in the pathogenesis of X-linked agammaglobulinaemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice. We have isolated phage and cosmid clones that allowed us to deduce the genomic structure of mouse and...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Sideras, P, Müller, S, Shiels, H, Jin, H, Khan, W, Nilsson, L, Parkinson, E, Thomas, J, Brandén, L, Larsson, I
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	1994

Antzeko izenburuak

Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.
nork: Müller, S, et al.
Argitaratua: (1996)

X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.
nork: Smith, C, et al.
Argitaratua: (1998)

498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.
nork: Thomas Kartika, et al.
Argitaratua: (2024-04-01)

Comparative CNS Pharmacology of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
nork: Timothy J. Turner, et al.
Argitaratua: (2024-07-01)

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
nork: Sze-Ting Bong, et al.
Argitaratua: (2019-05-01)

Expression of Bruton's tyrosine kinase in osteoclasts
nork: Danks, L, et al.
Argitaratua: (2005)

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
nork: Strijbis, Karin, et al.
Argitaratua: (2018)

Vegetative skin lesions in patient with bruton's agammaglobulinemia
nork: Cristian Fidanzi, et al.
Argitaratua: (2023-01-01)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
nork: Xiaoyu Feng, et al.
Argitaratua: (2023-08-01)

Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
nork: Gita Manzari Tavakoli, et al.
Argitaratua: (2024-08-01)

QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton’s tyrosine kinase (BTK) inhibitors
nork: Mourad Aloui, et al.
Argitaratua: (2024-01-01)

DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinaemia.
nork: Vorechovský, I, et al.
Argitaratua: (1995)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
nork: Obada Ababneh, et al.
Argitaratua: (2022-05-01)

Novel BTK Mutation in Patient with Late Diagnosis of X-Linked Agammaglobulinemia
nork: Amanpreet Kalkat, et al.
Argitaratua: (2023-01-01)

Covalent cysteine targeting of Bruton’s tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells
nork: Logie, Emilie, et al.
Argitaratua: (2021)

Role of Bruton's Tyrosine Kinase in B Cell Development
nork: Alex Maas, et al.
Argitaratua: (2001-01-01)

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
nork: Laura Airas, et al.
Argitaratua: (2024-04-01)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
nork: Kim Linton, et al.
Argitaratua: (2023-08-01)

Identification of a novel BTK variant in a Chinese family with X-linked agammaglobulinemia
nork: ZHANG Han, SUN Yang, WANG Rong-rong, ZHANG Wen, ZHANG Xue
Argitaratua: (2021-04-01)

Investigation of a synonymous mutation in Btk in a patient with agammaglobulinemia: A case report
nork: Cindy Srinivasan, et al.
Argitaratua: (2023-10-01)

Lack of Bruton's tyrosine kinase results in osteoporosis, despite defects in osteoclast function
nork: Danks, L, et al.
Argitaratua: (2007)

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
nork: Shannon Meledathu, BS, et al.
Argitaratua: (2024-12-01)

PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases
nork: Can Zhu, et al.
Argitaratua: (2024-08-01)

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
nork: Issei Nakade, et al.
Argitaratua: (2023-11-01)

PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
nork: Kim Linton, et al.
Argitaratua: (2023-08-01)

Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
nork: Horwood, N, et al.
Argitaratua: (2003)

Elucidation of the role of Bruton's tyrosine kinase in toll-like receptor 3 signaling.
nork: Yue, Shin Yen.
Argitaratua: (2008)

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
nork: Qiu-Sha Huang, et al.
Argitaratua: (2023-08-01)

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
nork: Ragha V. Suresh, et al.
Argitaratua: (2023-08-01)

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response
nork: Lee, K.-G., et al.
Argitaratua: (2013)

Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2
nork: Nocka, Laura M., et al.
Argitaratua: (2023)

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor
nork: Alison H. Kucharik, MD, et al.
Argitaratua: (2024-09-01)

Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
nork: Ye Liu, et al.
Argitaratua: (2023-12-01)

Bruton's tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
nork: O'Riordan, CE, et al.
Argitaratua: (2019)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
nork: Daniel Medina-Gil, et al.
Argitaratua: (2025-03-01)

Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia
nork: Lu-Lu Xu, et al.
Argitaratua: (2024-08-01)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
nork: Jonathan J. Pinney, et al.
Argitaratua: (2022-02-01)

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
nork: Yuqin Song, et al.
Argitaratua: (2023-10-01)

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies
nork: Mohammed Alrouji, et al.
Argitaratua: (2023-10-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
nork: Dariusz Rozkiewicz, et al.
Argitaratua: (2023-03-01)